Agios | pharmaphorum

Thursday 9 April 2026

Agios

News

Agios' chief medical officer, Sarah Gheuens

Agios mulls early FDA filing for sickle cell therapy

Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

News

Agios HQ

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

R&D

This week in clinical trials

3rd to 7th June – This week in clinical trials

In this instalment of our clinical trials round-ups, we look at life sciences research and development announced during the week of 3rd to 7th June, from early-stage onwards.

R&D

clinical trials

This week in clinical trials: 2nd-5th January 2024

Despite the multiple challenges that faced clinical trials in 2023, according to GlobalData’s Pharmaceutical Intelligence Centre, some 22,338

News

Servier’s $1.8bn Agios deal delivers glioma prospect

Servier’s $1.8bn Agios deal delivers glioma prospect

IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.

News

Servier gets a win for cancer drug Tibsovo, bought in $1.8bn...

Just three months after completing its $1.8 billion takeover of Agios' oncology pipeline, Servier has reported pos